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Abstract 18 
Background: Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat 19 
expansion in the huntingtin (HTT) gene. Metabolic changes are associated with HD progression, 20 
and underlying mechanisms are not fully known. As the IKKβ/NF-kB pathway is an essential 21 
regulator of metabolism, we investigated the involvement of IKKβ, the upstream activator of NF-22 
kB in hypothalamus-specific HD metabolic changes. 23 
Methods: Using viral vectors, we expressed amyloidogenic N-terminal fragments of mutant HTT 24 
(mHTT) fragments in the hypothalamus of mice without IKKβ in the CNS (IKKβ-/-) and control 25 
mice (IKKβ+/+). We assessed effects on body weight, metabolic hormones, and hypothalamic 26 
neuropathology.  27 
Results: Hypothalamic expression of mHTT led to an obese phenotype only in female mice. CNS-28 
specific inactivation of IKKβ prohibited weight gain in females, which was independent of 29 
neuroprotection and microglial activation.  30 
Conclusions: The expression of mHTT in the hypothalamus causes metabolic imbalance in a sex-31 
specific fashion, and central inhibition of the IKKβ pathway attenuates the obese phenotype. 32 
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Introduction 37 
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion 38 
in the huntingtin (HTT) gene (HDCRG, 1993). Although the clinical diagnosis is based on typical 39 
motor symptoms, affected individuals also suffer from non-motor symptoms such as cognitive 40 
decline, psychiatric symptoms, and metabolic disturbances, which often precede motor symptoms 41 
by several years (Bates et al., 2015; Cheong, Gabery, & Petersen, 2019). Metabolic changes in HD 42 
include weight loss despite adequate or even higher caloric intake (Aziz et al., 2008; Marder et al., 43 
2009). A higher baseline body mass index (BMI) has been associated with a slower disease 44 
progression (van der Burg et al., 2017). Hence, identifying the underlying mechanisms of 45 
metabolic changes in HD may reveal novel targets for therapeutic interventions to modify disease 46 
progression.    47 
The hypothalamus is a master regulator of metabolism (Cakir & Nillni, 2019; Timper & 48 
Bruning, 2017). Imaging studies have identified hypothalamic changes in both prodromal and 49 
symptomatic HD patients  (Douaud et al., 2006; Kassubek, Gaus, & Landwehrmeyer, 2004; Politis 50 
et al., 2008; Soneson et al., 2010). Analyses of postmortem hypothalamic tissue from HD cases 51 
and animal models (Cheong et al., 2019) showed loss of neuronal populations expressing orexin 52 
(hypocretin), oxytocin, and vasopressin, as well as altered metabolic pathways in several nuclei 53 
(Baldo et al., 2019; Gabery, Halliday, Kirik, Englund, & Petersen, 2015; Gabery et al., 2010; 54 
Petersen et al., 2005). Inactivation of mutant HTT (mHTT) selectively in the hypothalamus in the 55 
transgenic BACHD mouse model prevented developing a metabolic phenotype with obesity 56 
accompanied by leptin and insulin resistance (Gray et al., 2008; Hult et al., 2011). Similarly, local 57 
expression of mHTT in the hypothalamus using recombinant adeno-associated viral (rAAV) 58 
vectors in mice led to hyperphagic obesity with leptin and insulin resistance (Hult et al., 2011; 59 
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Soylu-Kucharz, Adlesic, Baldo, Kirik, & Petersen, 2015). Transgene expression was present in 60 
several appetite-regulating hypothalamic cell populations (i.e., AGRP, POMC)(Hult et al., 2011). 61 
As a result, even though these experiments have proved a causal link between hypothalamic 62 
expression of mHTT and the development of metabolic imbalance in mice, the mechanisms of 63 
hypothalamic mHTT induced metabolic imbalance are still unknown.    64 
The inhibitor of κB kinase β/ nuclear factor-κB (IKKβ/NF-κB) signaling pathway plays a 65 
significant role in obesity and overeating and is enriched in the hypothalamus (Meng & Cai, 2011; 66 
X. Zhang et al., 2008). Hyperphagia has been shown to activate IKKβ/NF-κB in the hypothalamus 67 
through increased endoplasmic reticulum stress, and suppression of IKKβ/NF-κB results in 68 
reduced food intake and normalized metabolic phenotype in mice (Douglass, Dorfman, Fasnacht, 69 
Shaffer, & Thaler, 2017; X. Zhang et al., 2008; Y. Zhang, Reichel, Han, Zuniga-Hertz, & Cai, 70 
2017). The IKKβ/NF-kB pathway is also activated by mHTT and has been associated with HD 71 
pathogenesis (Atwal et al., 2011; Becanovic et al., 2015; Khoshnan et al., 2004; Sarkar et al., 2011; 72 
Thompson et al., 2009; Trager et al., 2014). In the R6/1 mouse model of HD, brain-specific 73 
deletion of IKKβ impaired the behavioral phenotype and led to exacerbated neurodegeneration 74 
with an activated microglial response in the striatum (Ochaba et al., 2019). However, it is not 75 
known whether the IKKβ/NF-κB pathway is involved in the development of HD metabolic 76 
imbalance. In the present study, our aim was to determine whether inactivation of the IKKβ/NF-77 
κB pathway would prevent hypothalamic-induced metabolic changes induced by mHTT. We 78 
therefore performed injections of rAAV vectors expressing mHTT into the hypothalamus of mice 79 
without IKKβ in the CNS (IKKβ-/-) and compared metabolic effects to control mice with the floxed 80 
allele of IKKβ (IKKβ+/+).  81 
Materials and methods 82 
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Animals 83 
The experimental procedures performed on mice were carried out using the approved guidelines 84 
in the ethical permit approved by the Lund University Animal Welfare and Ethics committee in 85 
the Lund-Malmö region (ethical permit numbers M20-11 and M65-13). Generation of IKKβlox/lox 86 
(referred to as IKKβ+/+) mice (Li, Omori, Labuda, Karin, & Rickert, 2003) and Nestin-Cre mice 87 
(Betz, Vosshenrich, Rajewsky, & Muller, 1996) was described previously. Nestin/IKKβlox/lox 88 
(referred to as IKKβ-/-) mice were generated following several generations of backcrossing. Mice 89 
were obtained through crossing IKKβ-/- mice with IKKβ+/+ mice. The experiments were carried out 90 
on 2-6 months old mice old, both male and female mice, with the genotypes of IKKβ-/- mice and 91 
their IKKβ+/+ WT littermates. Genotyping for IKKβ+/+ was performed using the following primer 92 
sequence 5'-GTC ATT TCC ACA GCC CTG TGA-3' and 5'-CCT TGT CCT ATA GAA GCA 93 
CAA C-3', as described previously (Chen et al., 2003). The animals were kept at 12 hours night/day 94 
cycle with free access to a standard chow diet and water. 95 
 96 
Adeno-associated viral vectors 97 
To investigate the effect of the IKK pathway on the development of the metabolic phenotype, we 98 
performed stereotactic injections of recombinant adeno-associated viral (rAAV) vectors into the 99 
hypothalamus of IKKβ+/+ and IKKβ-/- mice. The viral vector was a pseudotyped rAAV2/5 vector 100 
(transgene was flanked by two inverted terminal repeats of the AAV2 and packaged in an AAV5 101 
capsid), where the human mHTT gene of 853 amino acids length (853HTT79Q) (Hult et al., 2011). 102 
The human Synapsin-1 promoter drove the mHTT gene expression.  103 
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 104 
Viral vector injections 105 
The animals were anesthetized by air mask inhalation of isoflurane (2% isoflurane in O2/N2O 106 
(3:7)). The mouse head was fixed with a nose clamp and ear bars in the stereotaxic apparatus. 107 
Following the head position's fine-tuning on the stereotaxic frame, the skull was thinned with a 108 
dental drill to make a borehole at the determined anterior-posterior and medial-lateral 109 
hypothalamic coordinates. Subsequently, the final dorsal-ventral coordinates were measured from 110 
the dura mater. The stereotaxic coordinates chosen for hypothalamic injections were: 0.6 mm 111 
posterior to bregma, -0.6 mm lateral to the bregma, and 5.2 mm ventral to the dura mater, selected 112 
according to the mouse brain atlas (Franklin & Paxinos, 2008). 113 
The rAAV vector delivery was performed bilaterally in the hypothalamus. The silica glass 114 
capillary (with an outer diameter of ~ 80 μm) attached to a 5 μl Hamilton syringe (Nevada, USA) 115 
was used for the virus delivery. A total volume of 0.5 μl viral vector solution was pulled in a glass 116 
capillary, and the capillary was descended from dura mater to target coordinates slowly. At the 117 
target, the first 0.1 μl of the total volume was injected. After 30 seconds, the viral suspension was 118 
delivered at a rate of 0.05μl/15s until the whole volume was delivered. To allow the brain to absorb 119 
the viral vector solution, the capillary was left at the target for an additional 5 minutes at the end 120 
of the injection. The viral vector concentration used in the study was 2,1E+14 genome copies 121 
(GC)/ml. 122 
 123 
Perfusion and serum collection  124 
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To induce deep anesthesia in mice, a terminal dose of pentobarbital (600 mg/kg, Apoteksbolaget) 125 
was injected intraperitoneally. The thoracic cavity was opened to expose the heart, and blood was 126 
collected from the right ventricle with the 16G needle. Subsequently, a small incision was made 127 
to insert a 12-gauge perfusion needle at the tip of the left ventricle. First, the vessels were rinsed 128 
with the saline solution at a rate of 10-12 ml/min for a minute, and then it was switched to freshly 129 
prepared 4% paraformaldehyde (PFA) ~0°C for 8 minutes. Following that, the animals were 130 
decapitated, and the brains were isolated. The brains were placed in 4% PFA for 24 hours at 4°C 131 
for post-fixation. Next, the PFA was replaced with 25% sucrose solution at 4°C for cryoprotection 132 
(~24 hours).  133 
Finally, the fixed brains were sectioned coronally on a semi-automated freezing microtome 134 
(Microm HM 450) at 30 μm thick slices and in six series. Until further processing, the brain 135 
sections were stored in antifreeze solution (30% glycerol and 30% ethylene glycol in phosphate 136 
buffer) at −20 °C. 137 
 138 
Metabolic Measurements 139 
Serum insulin and leptin concentrations were assessed in blood collected from the heart left 140 
ventricle prior to perfusion. The blood was kept at room temperature for 30 minutes to clot and 141 
spun for 15 minutes at 2500 g. The serum (supernatant) was stored at -80 C. Serum levels of insulin 142 
(Crystal Chem Inc, Catalog #90080) and leptin (Crystal Chem Inc, Catalog #90030) were assessed 143 
using ELISA according to the manufacturer's instructions. 144 
 145 
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Immunohistochemistry  146 
The free-floating brain sections were used for immunohistochemistry (IHC). All the washing steps 147 
(10 minutes/wash) and incubations were performed using gentle agitation on a shaker at room 148 
temperature. The sections were washed three times in Tris-buffered-saline (TBS) in 1% Triton X 149 
(TBS-T) to remove the antifreeze solution. The endogenous peroxidase activity was blocked by 150 
30 minutes of incubation in 10% methanol with 3% H2O2 in TBS. Following that, the sections 151 
were washed three times for 10 minutes in TBS-T. The sections were incubated with 5% serum 152 
and bovine serum albumin (BSA) in TBS-T for 1 hour to reduce nonspecific binding of the primary 153 
and secondary antibodies. Next, the sections were left in the respective primary antibody solutions 154 
in 3% appropriate corresponding serum in TBS-T (anti-huntingtin (sc-8767; 1:500; goat; Santa 155 
Cruz), anti-ubiquitin (1:2000; rabbit; Dako), anti-orexin (1:4000; rabbit; Phoenix 156 
Pharmaceuticals), anti-tyrosine hydroxylase (1:2000; rabbit; Pel-Freez), anti-GnRH (1:3000, anti-157 
rabbit, Abcam #ab5617), anti-iba-1) and left on shaker for overnight incubation at room 158 
temperature. Next, sections were washedthree3 times for 10 minutes in TBS-T. The secondary 159 
antibody incubation was performed in 3% respective serum or BSA with TBS-T for 1 hour at room 160 
temperature, and the sections were washed three times for 10 minutes in TBS before 3,3′-161 
diaminobenzidine (DAB) development (Vectastain, ABC kit). Brain sections were mounted on 162 
chromatin-gelatin coated glass slides. The air-dried sections were left in distilled water for 1 163 
minute and dehydrated in increasing ethanol solutions (70%, 95%, 99%). Finally, the samples were 164 
cleared in xylene and covered with glass coverslips using DPX mounting medium (Sigma-165 
Aldrich). 166 
 167 
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Stereological analyses 168 
To estimate the numbers of cells positive for orexin, TH, GnRH (in the anterior hypothalamus; 169 
AHA), and size of the inclusions, we applied unbiased stereological quantification principles by 170 
using the optical dissector method (West, Slomianka, & Gundersen, 1991). Stereological analyses 171 
were performed with a Nikon 80i microscope, which is equipped with an X–Y motorized stage 172 
(Märzhauser, Wetzlar) and a high precision linear encoder (Heidenhain, Traunreut). The position 173 
of the stage and the input from the digital camera were controlled by a computer. The sampling 174 
interval was adjusted to count at least 100 cells for each hypothalamus to minimize the coefficient 175 
of error. The region of interest was delineated under the 4X objective, whereas the counting was 176 
performed using a 60X NA 1.4 Plan-Apo oil objective with a random start systematic sampling 177 
routine (NewCast Module in VIS software; Visiopharm A/S, Horsholm). The border delineation 178 
processes for orexin, TH, GnRH cell populations were defined by the natural contours of cell 179 
populations. The number and size of iba-1 positive microglia/macrophages were quantified in the 180 
anatomical borders of the mediobasal hypothalamus. The number of small, medium and large size 181 
HTT inclusions was quantified with HTT staining (sc-6787). The inclusions ~ 0.04 - 0.1 μm size 182 
considered small, 0.15 - 0.25 μm medium and ~ 0.25-0.5 μm large size inclusions. The same size 183 
of the area was quantified for all genotypes and gender under blinded conditions. The mean number 184 
of assessed inclusions per brain was 755, median 663 with a standard deviation of error 528 185 
inclusions.  186 
 187 
Metabolic tests 188 
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For all animals used in the study, body weight was measured bimonthly. Serum insulin and leptin 189 
concentrations were assessed in serum. Blood was collected from the heart left ventricle at 18 190 
weeks post-injection, and they were kept at room temperature for 30 minutes to clot, spun for 15 191 
minutes at 2500 g. Serum (supernatant) was aliquoted and stored at -80 C. Serum levels of leptin 192 
(Crystal Chem Inc, Catalog #90030) and testosterone (Demeditec, Cat.-No.: DEV9911) were 193 
determined with ELISA according to the manufacturer's instructions. 194 
 195 
Statistical analysis 196 
All statistical analyses were performed using Prism 8 software (GraphPad). The data was initially 197 
tested with D'Agostino & Pearson omnibus normality test for normal distribution. Following that, 198 
the data was either subjected to Kruskal–Wallis followed by Dunn's multiple comparison tests or 199 
an unpaired t-test with equal SD. The statistical test results and the type of analysis used for each 200 
experiment are specified in detail in the results section and figure legends. Statistically significant 201 
differences were considered for p<0.05.  202 
 203 
Results 204 
Inhibition of the IKKβ pathway protects from hypothalamic mHTT-induced obesity in 205 
female mice 206 
To assess the effects of mHTT expression on the development of a metabolic phenotype, we 207 
injected IKKβ+/+ (homozygous for the floxed allele of IKKβ, control group) and IKKβ-/- 208 
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(expressing Cre-recombinase under nestin promotor) mice with rAAV vectors expressing mHTT 209 
(AAV5-853HTT79Q vectors are referred to as HD elsewhere) in the hypothalamus of both sexes. 210 
Consistent with our previous findings (Baldo, Soylu, & Petersen, 2013; Hult et al., 2011; Soylu-211 
Kucharz et al., 2015), expression of mHTT in female control mice led to an obese phenotype 212 
(Figure 1A, C). The body weight at 18 weeks post-injection was significantly higher in the 213 
IKKβ+/+HD mice (n=16 and mean= 55.6g, SD=10.2) compared to IKKβ-/-HD mice (n=20 and 214 
mean=40.6g, SD=9.3, p<0.0001) and uninjected mice of the two genotypes (uninjected IKKβ+/+: 215 
n=15 and mean=43.7g, SD=7.4, p=0.0026; uninjected IKKβ-/-: n=13 and mean=37.1g, SD=9.8, 216 
p<0.0001). Hence, inactivation of the IKKβ pathway in Nestin-expressing cells protected female 217 
mice from hypothalamic mHTT induced obesity (Figure 1A). The brain-specific deletion of IKKβ 218 
did not affect the circulating insulin and leptin levels in mice (Meng & Cai, 2011). Therefore, in 219 
this study, we assessed the serum levels of insulin and leptin levels only in mice expressing mHTT 220 
in the hypothalamus. In line with the prevention of body weight gain, IKKβ-/-HD mice displayed 221 
significantly lower serum levels of insulin and leptin than IKKβ+/+HD mice (Figure 1D).  222 
IKKβ did not affect the body weight in male mice with or without injections of AAV5-223 
853HTT79Q as assessed up to 18 weeks post-injection (Figure 1B, F). However, analyses of 224 
serum levels of insulin and leptin showed that even though there was no effect on body weight, 225 
levels of insulin and leptin were significantly elevated in IKKβ-/-HD mice compared to IKKβ+/+HD 226 
mice (Figure 1G and 1H).  227 
 228 
IKKβ is not involved in the mHTT-mediated loss of orexin and TH positive cell populations 229 
in HD mice 230 
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The development of the metabolic phenotype in HD has been associated with expression of mHTT 231 
in the hypothalamus (Hult et al., 2011; Soylu-Kucharz et al., 2015). Here we tested whether the 232 
rescue of the metabolic phenotype observed in IKKβ-/-HD mice was due to the preservation of 233 
metabolism-regulating neuronal populations known to be affected in HD (Cheong et al., 2019). In 234 
female mice, there was no benefit of IKKβ silencing as the number of orexin positive cells was 235 
comparable in IKKβ+/+HD (cell loss ~64%) and IKKβ-/-HD groups (cell loss ~82%), and both 236 
groups had a significantly lower number of orexin cells compared to uninjected groups of female 237 
mice (Figure 2A and 2B). Male IKKβ-/-HD mice had significantly lower orexin and A13 TH 238 
positive cells than IKKβ+/+HD mice in the hypothalamus (Supplementary Figure 1A and 1B).  239 
The loss of A13 TH positive cells was ~80% in IKKβ-/-HD and ~65% in IKKβ+/+HD when 240 
compared to WT and IKKβ-/- uninjected female mice (Figure 2C and 2D).  241 
Reduced testosterone levels are associated with increased circulating levels of leptin and 242 
insulin, even in the absence of increased BMI (Luukkaa et al., 1998; Pitteloud et al., 2005). The 243 
hypothalamic-pituitary-gonadal (HPG) axis, which regulates testosterone production, is altered in 244 
HD (Bird, Chiappa, & Fink, 1976; Kalliolia et al., 2015; Markianos, Panas, Kalfakis, & 245 
Vassilopoulos, 2005; Papalexi et al., 2005; Petersen & Bjorkqvist, 2006; Saleh et al., 2009; Soylu-246 
Kucharz, Baldo, & Petersen, 2016; Van Raamsdonk et al., 2007). The number of GnRH positive 247 
cells was comparable (Figure 2F and Supplementary Figure 1C); however, the total circulating 248 
level of testosterone was diminished in IKKβ-/-HD male mice by 60% compared to IKKβ+/+HD 249 
male mice expressing mHTT in the hypothalamus (Supplementary Figure 1D).  250 
 251 
The number or size of Iba-1 positive microglial cells in the mediobasal hypothalamus. 252 
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Given that IKKβ is one of the mediators of microglial activation and energy balance (Karin, 1999; 253 
Liu, Zhang, Joo, & Sun, 2017), we investigated whether protection from hypothalamic mHTT 254 
induced obesity in IKKβ-/- female mice was due to alteration in microglial activation. Nonetheless, 255 
the number and size of Iba1 positive cells in the mediobasal hypothalamus of both IKKβ+/+HD and 256 
IKKβ-/-HD female mice were comparable (Figure 3A-C).  257 
IKKβ-/-HD female mice display an increased number of small-sized inclusions of mHTT 258 
Reduction of IKKβ activity decreases the cleavage of both WT and mHTT and prevents the 259 
accumulation of mHTT inclusions (Khoshnan, Ko, Tescu, Brundin, & Patterson, 2009; Thompson 260 
et al., 2009). IKKβ silencing studies also showed impaired clearance of mHTT and worsening HD 261 
pathological phenotypes in vivo and vitro (Khoshnan et al., 2009; Thompson et al., 2009). In our 262 
model, inclusions were increased in IKKβ-/-HD compared to IKKβ+/+HD in both female and male 263 
mice (Figure 4A-C). The small size inclusions were responsible for the increase, as the number 264 
of medium or large size inclusions were similar between IKKβ+/+HD and IKKβ-/-HD groups 265 
(Figure 4D-F).  Altogether, these results show the increase in inclusion formation correlates with 266 
previous reports on IKKβ silencing in HD (Criollo et al., 2010; Khoshnan et al., 2009; Ochaba et 267 
al., 2019). 268 
 269 
Discussion 270 
Alterations in energy metabolism may affect disease progression in HD as weight loss is part of 271 
the clinical phenotype, and a higher BMI has been associated with the slower clinical decline (van 272 
der Burg et al., 2017). Understanding the underlying biological cause of metabolic disturbances in 273 
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HD may unravel novel therapeutic targets for this fatal neurodegenerative disorder. The IKKβ/NF-274 
kB pathway has been implicated in HD pathogenesis (Khoshnan & Patterson, 2011), but it has not 275 
been investigated in the context of HD metabolic and hypothalamic alterations. Here, we expressed 276 
mHTT in the hypothalamus of control mice and compared effects to mice with IKKβ inactivated 277 
in the CNS. We found that hypothalamic mHTT expression induces obese phenotype selectively 278 
in the female mice and inactivation of the IKKβ prevents it. Gender differences play a role in HD 279 
as the severity and rate of the motor symptoms progression has been suggested to be faster in 280 
women than men with HD (Zielonka et al., 2013; Zielonka et al., 2018; Zielonka & Stawinska-281 
Witoszynska, 2020). Previous studies indicated that sex also affects the HD metabolic and 282 
behavioral manifestation in animal models (Dorner, Miller, Barton, Brock, & Rebec, 2007; 283 
Sjogren et al., 2019; Soylu-Kucharz et al., 2016). Even though the expression of mHTT in the 284 
hypothalamus of male mice did not affect body weight, male IKKβ-/-HD displayed high serum 285 
leptin and insulin levels. As testosterone deficiency is associated with metabolic syndrome 286 
exemplified by increased circulating leptin levels and insulin resistance, it is possible that the 287 
increase in serum leptin and insulin levels could be due to reduced circulating testosterone levels 288 
in IKKβ-/-HD mice.  289 
Obese phenotype can occur due to increased caloric intake, decreased activity, metabolic 290 
rate, or combination of these factors. Previously, we demonstrated that the obese phenotype caused 291 
by hypothalamic mHTT expression was due to hyperphagia as general motor activity and basal 292 
metabolic rate were unaltered in these mice (Hult et al., 2011). The mice in this study were housed 293 
in a separate animal unit that lacks behavior testing platforms and limiting the number of in-house 294 
cages. Therefore, we were not able to re-test basic parameters such as food intake and locomotor 295 
activity. However, as we have previously shown that obese phenotype was caused by increased 296 
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food intake, we speculate that the silencing of the IKKβ expression prohibited hyperphagia-297 
induced obesity in HD mice. The orexin and A13 TH neuronal populations are involved in 298 
metabolism regulation (Adeghate et al., 2020; Shi et al., 2013) and they are affected in HD (Gabery 299 
et al., 2010; Hult et al., 2011; Petersen et al., 2005; Soylu-Kucharz et al., 2015). As the inactivation 300 
of the IKKβ signaling did not affect the preservation of these cells, we can speculate that orexin 301 
and A13 TH neuropathology are not the central cell populations responsible for the development 302 
of HD bodyweight alterations.  303 
In conclusion, our study shows that hypothalamic expression of mHTT leads to a metabolic 304 
imbalance in a sex-specific fashion. The weight gain phenotype induced by the mHTT in female 305 
mice is prevented by IKKβ inactivation and is independent of orexin TH neuroprotection, and 306 
microglial activation.  307 
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Figure 1: Inactivation of the IKKβ pathway inhibits the development of obesity-induced by 318 
mHTT expression in the hypothalamus of female mice 319 
 IKKβ+/+ and IKKβ-/- mice were injected bilaterally into the hypothalamus with AAV-HTT853-320 
79Q vectors and assessed using metabolic analyses. (A) Female IKKβ+/+ mice develop increased 321 
body weight after hypothalamic injections of AAV5-HTT853-79Q vectors which is prevented in 322 
IKKβ-/- female mice (two-way repeated measures ANOVA, effect of time F (2, 62) = 8.920, 323 
p<0.0001; effect of genotype F (1, 31) = 20.83, p<0.0001; effect of genotype x time F (2, 62) = 324 
8.920, p=0.0004; followed by a Sidak's multiple comparisons test: p= 0.0026 at 8 weeks and p< 325 
0.0001 at 18 weeks). (B) Male IKKβ+/+ and IKKβ-/- mice do not develop obesity after AAV5-326 
HTT853-79Q vector injections (two-way repeated measures ANOVA, effect of time F (2, 72) = 327 
190.4, P < 0.0001; effect of genotype F (1, 36) = 2.359, P = 0.1333; effect of genotype x time F 328 
(2, 72) = 1.446, P = 0.2422, followed by a Sidak's multiple comparisons test). (C) Body weight 329 
changes at 18 weeks post-injection in females (One-way ANOVA, effect of treatment F (3, 60) = 330 
11.69, P<0.0001 followed by Sidak's multiple comparisons test). Serum (D) insulin (two-tailed, 331 
unpaired t-test, n=16/19, p=0.0082) and (E) leptin (two-tailed, Mann Whitney test, n=16/19, 332 
p=0.0003) concentrations measured by ELISA in females at 18 weeks post injection. (F) Body 333 
weight changes at 18 weeks post-injection in males (One-way ANOVA, effect of treatment F (3, 334 
55) = 0.7312", P=0.5378 followed by Sidak's multiple comparisons test). Serum (G) insulin (two-335 
tailed, Mann Whitney test, n=15/21, p=0.0448) and (H) leptin (two-tailed, unpaired t-test, 336 
n=15/21, p=0.0023) assessments at 18 weeks. Data are represented as box and whisker plots (25–337 
75 percentile (boxes), min to max (whiskers), median (horizontal line), mean (+)). 338 
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Figure 2: Quantitative analysis of the neuronal populations expressing orexin, TH in the A13 340 
area, and GnRH in female mice at 18-week post-injection of AAV-HTT853-79Q vectors. (A) 341 
Representative immunohistochemically stained sections show orexin immunopositive cells in the 342 
hypothalamus. (B) Stereological analysis of orexin immunopositive cells in female mice at the 18 343 
weeks time point (Kruskal-Wallis test followed by Dunn's multiple comparisons test p=0.0002; 344 
n=4-8/group). (C) Representative photomicrographs show the A13 TH immunopositive cell 345 
population in the hypothalamus. (D) Numbers of A13 TH positive cells in the hypothalamus's zona 346 
incerta area (Kruskal-Wallis test followed by Dunn's multiple comparisons test p=0.0001; n=4-347 
9/group). (E) Representative photomicrographs illustrate the GnRH positive cells in the anterior 348 
hypothalamic area of the hypothalamus. (F) Stereological quantification of GnRH positive cells in 349 
the anterior hypothalamic area (Kruskal-Wallis test followed by Dunn's multiple comparisons 350 
p=0.0802; n=4-8/group). Points on scatter graphs represent total cell count for individual mice, the 351 
lines are means, and the whiskers indicate ± SEM. Scale bars represent 200 μm. 352 
 353 
Figure 3: No effect of the IKKβ pathway on the degree of iba-1 positive cell activation at 18 354 
weeks post-injection in females. Stereological assessment of (A) the total number of iba-1 355 
positive cells (two-tailed, unpaired t-test, n=7/8, p=0.477) and (B) the size of Iba-1 positive cells 356 
(two-tailed, Mann-Whitney test, n=7/8 animals, n=783/911 cells/genotype, p=0.9601) in the 357 
mediobasal hypothalamus (MBH) 18 weeks after injections of AAV5-HTT853-79Q vectors in 358 
IKKβ+/+ and IKKβ-/- mice. In (A), data are represented as scatter dot plots, and bars represent mean 359 
± SEM, and in (B), data are represented as scatter dot plots, and lines represent median. 360 
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Figure 4: Inactivation of the IKKβ pathway leads to increased numbers of huntingtin 362 
inclusions in the hypothalamus. Representative photomicrographs of sections processed for 363 
immunohistochemistry for (A) huntingtin (using the sc-8767 antibody) and (B) ubiquitin 364 
demonstrating the formation of inclusions in the hypothalamus after injections of AAV-HTT853-365 
79Q vectors in IKKβ+/+ and IKKβ-/- mice. Stereological quantification of sections processed with 366 
the huntingtin antibody show (C) the total number of inclusions (Females: two-tailed, Mann-367 
Whitney test, n=5/group, p=0.0008; Males: two-tailed, Mann-Whitney test, n=5/group, p<0.0001), 368 
(D) large-sized inclusions (Females: two-tailed, Mann-Whitney test, n=5/group, p=0.3095; Males: 369 
two-tailed, unpaired t-test, n=5/group, p=0.8992), (E) medium-sized inclusions (Females: two-370 
tailed, unpaired t-test, n=5/group, p=0.0635); Males: two-tailed, unpaired t-test, n=5/group, 371 
p=0.0911) and (F) small-sized inclusions (Females: two-tailed, Mann-Whitney test, n=5/group, 372 
p=0.0079; Males: two-tailed, unpaired t-test, n=5/group, p<0.0001) inclusions in female and male 373 
mice at 18 weeks post-injection. Points on scatter graphs represent total inclusion count for 374 
individual mice, the lines are means, and the whiskers indicate ± SEM. Scale bars represent 200 375 
μm and 25 μm on lower and higher magnifications, respectively. 376 
 377 
Supplementary figure 1: Effects on the orexin, GnRH, and A13 TH cell populations in the 378 
hypothalamus in male mice after injections of AAV-HTT853-79Q vectors. Stereological 379 
quantification of (A) orexin (two-tailed, unpaired t-test, n=8/group, p=0.001), (B) TH (two-tailed, 380 
unpaired t-test, n=8/group, p=0.0471) and (C) GnRH (two-tailed, unpaired t-test, n=7/group, 381 
p=0.3648) positive cells in IKKβ+/+ and IKKβ-/- males expressing mHTT in the hypothalamus at 382 
18 weeks post-injection. (D) Changes in serum testosterone levels in male IKKβ+/+ and IKKβ-/-383 
mice at 18 weeks post-injection of AAV-853HTT-79Q in the hypothalamus (two-tailed, Mann-384 
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Whitney test, n=8/14, p=0.0159). Data are represented as scatter dot plots, the lines are means, and 385 
the whiskers indicate ± SEM. 386 
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Figure 1
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Figure 2
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Figure 3
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Supplementary figure 1
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